 Oncogene Protein v maf |
| Oncogene Protein v-akt |
| Oncogene Protein v-akt [Chemical/Ingredient] |
| Oncogene Protein v-cbl |
| Oncogene Protein v-cbl [Chemical/Ingredient] |
| Oncogene Protein v-crk |
| Oncogene Protein v-crk [Chemical/Ingredient] |
| oncogene protein v-ets |
| Oncogene Protein v-fes |
| oncogene protein v-fps, Fujinami sarcoma virus |
| Oncogene Protein v-jun |
| Oncogene Protein v-maf |
| Oncogene Protein v-maf [Chemical/Ingredient] |
| oncogene protein v-sea |
| Oncogene Protein, cbl |
| Oncogene Protein, crk |
| Oncogene Protein, E2 Human Papillomavirus Type 18 |
| Oncogene Protein, E7 Human Papillomavirus Type 6 |
| Oncogene Protein, jun |
| Oncogene Protein, maf |
| Oncogene Protein, v-cbl |
| Oncogene Protein, v-crk |
| Oncogene Protein, v-maf |
| Oncogene Proteins |
| Oncogene Proteins [Chemical/Ingredient] |
| Oncogene Proteins erbB |
| Oncogene Proteins fos |
| Oncogene Proteins mos |
| Oncogene Proteins myb |
| Oncogene Proteins rel |
| Oncogene Proteins sis |
| Oncogene Proteins v abl |
| Oncogene Proteins v erbA |
| Oncogene Proteins v erbB |
| Oncogene Proteins v fos |
| Oncogene Proteins v mil |
| Oncogene Proteins v mos |
| Oncogene Proteins v myb |
| Oncogene Proteins v raf |
| Oncogene Proteins v rel |
| Oncogene Proteins v sis |
| Oncogene Proteins v-abl |
| Oncogene Proteins v-abl [Chemical/Ingredient] |
| Oncogene Proteins v-erbA |
| Oncogene Proteins v-erbA [Chemical/Ingredient] |
| Oncogene Proteins v-erbB |
| Oncogene Proteins v-erbB [Chemical/Ingredient] |
| oncogene proteins v-ets |
| Oncogene Proteins v-fos |
| Oncogene Proteins v-fos [Chemical/Ingredient] |
| Oncogene Proteins v-mil |
| Oncogene Proteins v-mos |
| Oncogene Proteins v-mos [Chemical/Ingredient] |
| Oncogene Proteins v-myb |
| Oncogene Proteins v-myb [Chemical/Ingredient] |
| Oncogene Proteins v-raf |
| Oncogene Proteins v-raf [Chemical/Ingredient] |
| Oncogene Proteins v-rel |
| Oncogene Proteins v-rel [Chemical/Ingredient] |
| Oncogene Proteins v-sis |
| Oncogene Proteins v-sis [Chemical/Ingredient] |
| Oncogene Proteins, abl |
| Oncogene Proteins, Chimeric |
| Oncogene Proteins, E7 |
| Oncogene Proteins, Fusion |
| Oncogene Proteins, Fusion [Chemical/Ingredient] |
| Oncogene Proteins, mos |
| Oncogene Proteins, myb |
| Oncogene Proteins, rel |
| Oncogene Proteins, sis |
| Oncogene Proteins, Viral |
| Oncogene Proteins, Viral [Chemical/Ingredient] |
| ONCOGENE PVT-1 |
| ONCOGENE QIN |
| ONCOGENE RAF1 |
| Oncogene RAS |
| ONCOGENE RCK |
| ONCOGENE REL |
| Oncogene RET |
| ONCOGENE RHO H12 |
| ONCOGENE RHO H6 |
| ONCOGENE RHO H9 |
| ONCOGENE RMYC |
| ONCOGENE ROS |
| ONCOGENE RRAS |
| ONCOGENE RRAS2 |
| ONCOGENE SEA |
| Oncogene SIS |
| ONCOGENE SK, CHICKEN VIRAL |
| Oncogene SKI |
| Oncogene SKI wt Allele |
| ONCOGENE SNO |
| ONCOGENE SPI1 |
| Oncogene SRC |
| ONCOGENE TIM |
| Oncogene TRK |
| Oncogene V-SIS |
| ONCOGENE VAV |
| ONCOGENE VAV1 |
| ONCOGENE VAV2 |
| ONCOGENE VAV3 |
| oncogene viral capsid protein L2, human papillomavirus type 33 |
| oncogene viral capsid protein, L1 human papillomavirus type 16 |
| oncogene viral capsid protein, L2 human papillomavirus type 16 |
| ONCOGENE WNT5A |
| Oncogene YES-1 |
| ONCOGENE YES1 |
| ONCOGENE YUASA |
| Oncogene, ABL |
| Oncogene, ABL1 |
| Oncogene, bcr-v-abl |
| Oncogene, C-Erb -2 |
| Oncogene, C-ErbB-2 |
| Oncogene, DBL |
| Oncogene, EGFR |
| Oncogene, ERBB2 |
| Oncogene, FPS-FES |
| Oncogene, jun |
| Oncogene, K-Ras |
| Oncogene, K-Ras-2 |
| Oncogene, MCF-2 |
| Oncogene, mos |
| Oncogene, myb |
| Oncogene, myc |
| Oncogene, NEU |
| Oncogene, Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene |
| Oncogene, NTRK1 |
| Oncogene, Recessive |
| Oncogene, rel |
| Oncogene, RET |
| Oncogene, sis |
| Oncogene, src |
| Oncogene, Transcription Factor |
| Oncogene, TRKA |
| Oncogene, v-abl |
| Oncogene, v-fms |
| Oncogene, v-mos |
| Oncogene, v-myb |
| Oncogene, v-myc |
| Oncogene, v-rel |
| Oncogene, v-sis |
| Oncogene, v-src |
| Oncogenes |
| Oncogenes, abl |
| Oncogenes, bcr-v-abl |
| Oncogenes, G-Proteins |
| Oncogenes, Growth Factor |
| Oncogenes, jun |
| Oncogenes, mos |
| Oncogenes, myb |
| Oncogenes, myc |
| Oncogenes, Nuclear Protein |
| Oncogenes, Protein-Kinase |
| Oncogenes, Recessive |
| Oncogenes, rel |
| Oncogenes, sis |
| Oncogenes, src |
| Oncogenes, Transcription Factors |
| Oncogenes, Tyrosine-Kinase |
| Oncogenes, v-abl |
| Oncogenes, v-fms |
| Oncogenes, v-mos |
| Oncogenes, v-myb |
| Oncogenes, v-myc |
| Oncogenes, v-rel |
| Oncogenes, v-sis |
| Oncogenes, v-src |
| Oncogenesis |
| ONCOGENIC LIPOCALIN 24P3 |
| Oncogenic Osteomalacia |
| Oncogenic Protein-Associated Protein E6-AP |
| Oncogenic Retroviridae Proteins |
| oncogenic suppression activity protein, Shigella flexneri |
| Oncogenic Virus |
| Oncogenic Viruses |
| oncogenic viruslike particle |
| Oncogens |
| oncoimmunin-M |
| ONCOL MED |
| ONCOL NURS |
| ONCOL RAD |
| ONCOL SERV HOSP |
| OncoLar |
| oncolipids |
| oncolipin |
 oncología |
 oncologia |
| Oncologic |
| Oncologic Complications |
| Oncologic Nursing |
| Oncologic Nursings |
| Oncologic Surgeon |
| oncologic surgery |
| oncological |
| Oncological Nursing |
| Oncological Nursings |
 oncologie |
 oncologie |
| Oncologist |
| oncologist, medical |
| Oncologist, Surgical |
| oncologist/hematologist, pediatric |
| Oncologist/Neurologist, Pediatric |
 oncologista |
| Oncologists |
| oncólogo |
| oncologo |
| oncologue |
| Oncology |
| oncology (field) |
| Oncology Certified Nurse |
| Oncology Consult note |
| Oncology Data Management Systems |
| Oncology drugs |
| Oncology E/M note |
| Oncology Evaluation and management note |
| oncology field |
| Oncology Group |
| Oncology Information Systems |
| Oncology Nurse |
| Oncology Nurse Specialist |
| Oncology Nursing |
| Oncology problem |
| Oncology Programs |
| Oncology Radiotherapy Information Management Systems |
| Oncology Referral note |
| Oncology Service, Hospital |
| Oncology Services, Hospital |
| Oncology tx decision-mgmt |
| Oncology work-up evaluation |
| Oncology, Clinical |
| oncology, dermatologic |
| Oncology, Experimental |
| oncology, gynecologic |
| Oncology, Medical |
| oncology, neurologic |
| Oncology, Other |
| Oncology, Pediatric |
| Oncology, Pediatrics |
| Oncology, Pediatrics - Clinical Nurse Specialist - NUCCProviderCodes |
| oncology, radiation |
| oncology, surgical |
| ONCOLOGY; DISEASE STATUS; CHRONIC MYELOGENOUS LEUKEMIA, LIMITED TO PHILADELPHIA CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE; ACCELERATED PHASE NOT IN HEMATOLOGIC CYTOGENETIC, OR MOLECULAR REMISSION (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; CHRONIC MYELOGENOUS LEUKEMIA, LIMITED TO PHILADELPHIA CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE; BLAST PHASE NOT IN HEMATOLOGIC, CYTOGENETIC, OR MOLECULAR REMISSION (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; CHRONIC MYELOGENOUS LEUKEMIA, LIMITED TO PHILADELPHIA CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE; CHRONIC PHASE NOT IN HEMATOLOGIC, CYTOGENETIC, OR MOLECULAR REMISSION (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; CHRONIC MYELOGENOUS LEUKEMIA, LIMITED TO PHILADELPHIA CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; CHRONIC MYELOGENOUS LEUKEMIA, LIMITED TO PHILADELPHIA CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE; EXTENT OF DISEASE UNKNOWN, UNDER EVALUATION, NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; CHRONIC MYELOGENOUS LEUKEMIA, LIMITED TO PHILADELPHIA CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE; IN HEMATOLOGIC, CYTOGENETIC, OR MOLECULAR REMISSION (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; COLON CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-3, N0, M0 WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE- |
| ONCOLOGY; DISEASE STATUS; COLON CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-4, N1-2, M0 WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICAR |
| ONCOLOGY; DISEASE STATUS; COLON CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T4, N0, M0 WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-AP |
| ONCOLOGY; DISEASE STATUS; COLON CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; COLON CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE WITH CURRENT CLINICAL, RADIOLOGIC, OR BIOCHEMICAL EVIDENCE OF DISEASE (FOR USE IN A |
| ONCOLOGY; DISEASE STATUS; COLON CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE WITHOUT CURRENT CLINICAL, RADIOLOGIC, OR BIOCHEMICAL EVIDENCE OF DISEASE (FOR USE I |
| ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-T3, N0-N1 OR NX (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE P |
| ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T4, ANY N, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRE |
| ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; GASTRIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; CLINICAL OR PATHOLOGIC M0, UNRESECTABLE WITH NO EVIDENCE OF DISEASE PROGRESSION, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; GASTRIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; CLINICAL OR PATHOLOGIC M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; GASTRIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; GASTRIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; POST R0 RESECTION (WITH OR WITHOUT NEOADJUVANT THERAPY) WITH NO EVIDENCE OF DISEASE RECURRENCE, PROGRESSION, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONS |
| ONCOLOGY; DISEASE STATUS; GASTRIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; POST R1 OR R2 RESECTION (WITH OR WITHOUT NEOADJUVANT THERAPY) WITH NO EVIDENCE OF DISEASE PROGRESSION, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATIO |
| ONCOLOGY; DISEASE STATUS; HEAD AND NECK CANCER, LIMITED TO CANCERS OF ORAL CAVITY, PHARYNX AND LARYNX WITH SQUAMOUS CELL AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-T2 AND N0, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO |
| ONCOLOGY; DISEASE STATUS; HEAD AND NECK CANCER, LIMITED TO CANCERS OF ORAL CAVITY, PHARYNX AND LARYNX WITH SQUAMOUS CELL AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T3-4 AND/OR N1-3, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH |
| ONCOLOGY; DISEASE STATUS; HEAD AND NECK CANCER, LIMITED TO CANCERS OF ORAL CAVITY, PHARYNX AND LARYNX WITH SQUAMOUS CELL AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION |
| ONCOLOGY; DISEASE STATUS; HEAD AND NECK CANCER, LIMITED TO CANCERS OF ORAL CAVITY, PHARYNX AND LARYNX WITH SQUAMOUS CELL AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION |
| ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJE |
| ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, UNDER EVALUATION, PRE-SURGICAL OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRA |
| ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJ |
| ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; STAGE I OR STAGE IIA-IIB; OR T3, N1, M0; AND ER AND/OR PR POSITIVE; WITH NO EVIDENCE OF DISEASE PROGRESSION, RECU |
| ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; STAGE I, OR STAGE IIA-IIB; OR T3, N1, M0; AND ER AND PR NEGATIVE; WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURR |
| ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; STAGE IIIA-IIIB; AND NOT T3, N1, M0; AND ER AND PR NEGATIVE; WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, |
| ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; STAGE IIIA-IIIB; AND NOT T3, N1, M0; AND ER AND/OR PR POSITIVE; WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURREN |
| ONCOLOGY; DISEASE STATUS; LIMITED TO MULTIPLE MYELOMA, SYSTEMIC DISEASE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; LIMITED TO MULTIPLE MYELOMA, SYSTEMIC DISEASE; SMOLDERING, STAGE I (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; LIMITED TO MULTIPLE MYELOMA, SYSTEMIC DISEASE; STAGE II OR HIGHER (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; EXTENT OF DISEASE INITIALLY ESTABLISHED AS STAGE I (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED |
| ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; EXTENT OF DISEASE INITIALLY ESTABLISHED AS STAGE II (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED |
| ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; EXTENT OF DISEASE INITIALLY ESTABLISHED AS STAGE III A (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPRO |
| ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; STAGE III B- IV AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL CELL; EXTENT OF DISEASE INITIALLY ESTABLISHED AS LIMITED WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PRO |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; DIAGNOSTIC EVALUATION, STAGE NOT DETERMINED, EVALUATION OF POSSIBLE RELAPSE OR NON-RESPONSE TO THERAPY, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; RELAPSED/REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; STAGE I, II AT DIAGNOSIS, NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; STAGE III, IV, NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; DIAGNOSTIC EVALUATION, STAGE NOT DETERMINED, EVALUATION OF POSSIBLE RELAPSE OR NON-RESPONSE |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; RELAPSED/REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; STAGE I, II AT DIAGNOSIS, NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMON |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; STAGE III, IV NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PRO |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, TRANSFORMED FROM ORIGINAL CELLULAR DIAGNOSIS TO A SECOND CELLULAR CLASSIFICATION (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA; TRANSFORMED FROM FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; EVIDENCE OF DISEASE PROGRESSION, OR RECURRENCE, AND/OR PLATINUM RESISTANCE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; PATHOLOGIC STAGE IA-B (GRADE 1) WITHOUT EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; PATHOLOGIC STAGE IA-B (GRADE 2-3); OR STAGE IC (ALL GRADES); OR STAGE II; WITHOUT EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRAT |
| ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; PATHOLOGIC STAGE III-IV; WITHOUT EVIDENCE OF PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PANCREATIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; POST R0 RESECTION WITHOUT EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PANCREATIC CANCER, LIMITED TO ADENOCARCINOMA; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PANCREATIC CANCER, LIMITED TO ADENOCARCINOMA; POST R1 OR R2 RESECTION WITH NO EVIDENCE OF DISEASE PROGRESSION, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PANCREATIC CANCER, LIMITED TO ADENOCARCINOMA; UNRESECTABLE AT DIAGNOSIS, M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; T1-T2C AND GLEASON 2-7 AND PSA < OR EQUAL TO 20 AT DIAGNOSIS WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED |
| ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; T2 OR T3A GLEASON 8-10 OR PSA > 20 AT DIAGNOSIS WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION |
| ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; T3B-T4, ANY N; ANY T, N1 AT DIAGNOSIS WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; AFTER INITIAL TREATMENT WITH RISING PSA OR FAILURE OF PSA DECLINE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; CASTRATE; CLINICAL METASTASES OR M1 AT DIAGNOSIS (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; HORMONE-REFRACTORY/ANDROGEN-INDEPENDENT (E.G., RISING PSA ON ANTI-ANDROGEN THERAPY OR POST-ORCHIECTOMY); CLINICAL METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; HORMONE-RESPONSIVE; CLINICAL METASTASES OR M1 AT DIAGNOSIS (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; NON-CASTRATE, INCOMPLETELY CASTRATE; CLINICAL METASTASES OR M1 AT DIAGNOSIS (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-2, N0, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURREN |
| ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-3, N1-2, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURR |
| ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T3, N0, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE |
| ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T4, ANY N, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRE |
| ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; SMALL CELL LUNG CANCER, LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL CELL; EXTENSIVE STAGE AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; DISEASE STATUS; SMALL CELL LUNG CANCER, LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT ADHERES TO GUIDELINES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES AS A RESULT OF PATIENT ENROLLMENT IN AN INSTITUTIONAL REVIEW BOARD APPROVED CLINICAL TRIAL (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT, AFTER BEING OFFERED TREATMENT CONSISTENT WITH GUIDELINES, HAS OPTED FOR ALTERNATIVE TREATMENT OR MANAGEMENT, INCLUDING NO TREATMENT (FOR USE IN A MEDICARE-APPROVED DEMO |
| ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE TREATING PHYSICIAN DISAGREES WITH GUIDELINE RECOMMENDATIONS (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES FOR OTHER REASON(S) NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES FOR REASON(S) ASSOCIATED WITH PATIENT COMORBID ILLNESS OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; PRACTICE GUIDELINES; PATIENT'S CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; PRIMARY FOCUS OF VISIT; EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF CANCER FOR WHOM NO CANCER DIRECTED THERAPY IS BEING ADMINISTERED OR ARRANGED AT PRESENT; CANCER DIRECTED THERAPY MIGHT BE CONSIDERED IN THE FUTURE (FOR USE IN A MEDICARE-AP |
| ONCOLOGY; PRIMARY FOCUS OF VISIT; OTHER, UNSPECIFIED SERVICE NOT OTHERWISE LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| ONCOLOGY; PRIMARY FOCUS OF VISIT; SUPERVISING, COORDINATING OR MANAGING CARE OF PATIENT WITH TERMINAL CANCER OR FOR WHOM OTHER MEDICAL ILLNESS PREVENTS FURTHER CANCER TREATMENT; INCLUDES SYMPTOM MANAGEMENT, END-OF-LIFE CARE PLANNING, MANAGEMENT OF PALLIAT |
| ONCOLOGY; PRIMARY FOCUS OF VISIT; SURVEILLANCE FOR DISEASE RECURRENCE FOR PATIENT WHO HAS COMPLETED DEFINITIVE CANCER-DIRECTED THERAPY AND CURRENTLY LACKS EVIDENCE OF RECURRENT DISEASE; CANCER DIRECTED THERAPY MIGHT BE CONSIDERED IN THE FUTURE (FOR USE IN |
| ONCOLOGY; PRIMARY FOCUS OF VISIT; TREATMENT DECISION-MAKING AFTER DISEASE IS STAGED OR RESTAGED, DISCUSSION OF TREATMENT OPTIONS, SUPERVISING/COORDINATING ACTIVE CANCER DIRECTED THERAPY OR MANAGING CONSEQUENCES OF CANCER DIRECTED THERAPY (FOR USE IN A MED |
| ONCOLOGY; PRIMARY FOCUS OF VISIT; WORK-UP, EVALUATION, OR STAGING AT THE TIME OF CANCER DIAGNOSIS OR RECURRENCE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT) |
| oncology/hematology, pediatric |
| oncology/neurology, pediatric |
| Oncolym |
| Oncolysin B |
| Oncolysis |
| Oncolytic |
| Oncolytic Ad5-Delta 24RGD |
| Oncolytic Adenovirus Ad5-Delta 24RGD |
| oncolytic adenovirus encoding GM-CSF |
| Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter |
| ONCOLYTIC VIROTHER |
| Oncolytic Virotherapies |
| Oncolytic Virotherapy |
| Oncolytic Virus |
| ONCOLYTIC VIRUS THER |
| Oncolytic Virus Therapies |
| Oncolytic Virus Therapy |
| Oncolytic Viruses |
| Oncomegas |
| Oncomegas australiensis |
| Oncomegas sp. PDO-2006 |
| Oncomegoides |
| Oncomegoides celatus |
| Oncomelania |
| Oncomelania hupensis |
| Oncomelania hupensis Gredler,1881 |
| Oncomelania minima |
| Oncomelania minima P. Bartsch, 1936 |
| Oncomerella |
| Oncomerella venosa |
| Oncomerella venosa (Lewis, 1895) |
| ONCOMETER, PLASMA, FOR CLINICAL USE |
| Oncometers |
| Oncometopia |
| Oncometopia nigricans |
| Oncometopia orbona |
| oncoming |
| oncoming traffic |
| oncoming train |
| oncomodulin |
| oncomodulin 1 |
| oncomodulin 2 |
| oncomodulin protein, human |
| oncomodulin protein, mouse |
| oncomodulin protein, rat |
| Onconase |
| Onconase/TAM |
| Onconase/Tamoxifen |
| Onconase/TMX |
| Onconeural Ventral Antigen-1 |
| ONCONEURONAL ANTIGEN MA2 |
| Onconida |
| Onconida alaini |
| Onconida tropis |
| Oncopeltus |
| Oncopeltus fasciatus |
| Oncophage |
| Oncophanes |
| Oncophanes pronotalis |
| Oncophanes sp. |
| Oncophanes sp. 1 AZR-2008 |
| Oncophorus |
| Oncophorus virens |
| Oncophorus wahlenbergii |
| Oncopodidae |
| Oncopodoidea |
| Oncopodura |
| Oncopodura crassicornis |
| Oncopoduridae |
| oncoprecipitin A |
| Oncoprotein |
| Oncoprotein 18 |
| oncoprotein 18 protein, human |
| oncoprotein 18, mouse |
| oncoprotein 18, rat |
| oncoprotein CLTCL-ALK |
| oncoprotein DEK, human |
| oncoprotein E2A-Pbx1 |
| oncoprotein E2A-Pbx1, isoform a |
| oncoprotein E2A-Pbx1, isoform b |
| oncoprotein induced transcript 3 |
| oncoprotein kinase Tpl2, human |
| ONCOPROTEIN MDM2 |
| oncoprotein p21 |
| oncoprotein p28GANK, mouse |
| Oncoprotein p53 |
| ONCOPROTEIN-INDUCED TRANSCRIPT 3, MOUSE, HOMOLOG OF |
| Oncoproteins |
| oncopterin |
| Oncopus |
| Oncopus malayanus |
| Oncopus malayanus (Schwendinger & Martens, 2004) |
| Oncopus sp. GG-1997 |
| Oncorhynchus |
| Oncorhynchus apache |
| Oncorhynchus apache (Miller, 1972) |
| Oncorhynchus clarki |
| Oncorhynchus clarkii |
| Oncorhynchus clarkii (Richardson, 1836) |
| Oncorhynchus gilae |
| Oncorhynchus gilae (Miller, 1950) |
| Oncorhynchus gorbuscha |
| Oncorhynchus gorbuscha (Walbaum, 1792) |
| Oncorhynchus keta |
| Oncorhynchus keta (Walbaum, 1792) |
| Oncorhynchus kisutch |
| Oncorhynchus kisutch (Walbaum, 1792) |
| Oncorhynchus masou |
| Oncorhynchus masou (Brevoort, 1856) |
| Oncorhynchus masou herpes virus |
| Oncorhynchus mykiss |
| Oncorhynchus mykiss (Walbaum, 1792) |
| Oncorhynchus mykiss Ab |
| Oncorhynchus mykiss Ab.IgE |
| Oncorhynchus mykiss Ab.IgE:ACnc:Pt:Ser:Qn |
| Oncorhynchus mykiss Ab.IgE.RAST class |
| Oncorhynchus mykiss Ab.IgE.RAST class:ACnc:Pt:Ser:Ord |
| Oncorhynchus mykiss Ab.IgG |
| Oncorhynchus mykiss Ab.IgG:ACnc:Pt:Ser:Qn |
| Oncorhynchus mykiss Ab.IgG.RAST class |
| Oncorhynchus mykiss Ab.IgG.RAST class:ACnc:Pt:Ser:Ord |
| Oncorhynchus mykiss Ab.IgG4 |
| Oncorhynchus mykiss Ab.IgG4:MCnc:Pt:Ser:Qn |
| Oncorhynchus mykiss Antibody.IgG4 |
| Oncorhynchus mykiss Antibody.IgG4:Mass Concentration:Point in time:Serum:Quantitative |
| Oncorhynchus mykiss Antibody.immunoglobulin E |
| Oncorhynchus mykiss Antibody.immunoglobulin E:Arbitrary Concentration:Point in time:Serum:Quantitative |
| Oncorhynchus mykiss Antibody.immunoglobulin E.RAST class |
| Oncorhynchus mykiss Antibody.immunoglobulin E.RAST class:Arbitrary Concentration:Point in time:Serum:Ordinal |
| Oncorhynchus mykiss Antibody.immunoglobulin G |
| Oncorhynchus mykiss Antibody.immunoglobulin G:Arbitrary Concentration:Point in time:Serum:Quantitative |
| Oncorhynchus mykiss Antibody.immunoglobulin G.RAST class |
| Oncorhynchus mykiss Antibody.immunoglobulin G.RAST class:Arbitrary Concentration:Point in time:Serum:Ordinal |
| Oncorhynchus mykiss antigen |
| Oncorhynchus mykiss ranavirus |
| Oncorhynchus nerka |
| Oncorhynchus nerka (Walbaum, 1792) |
| Oncorhynchus rhodurus |
| Oncorhynchus rhodurus Jordan & McGregor, 1925 |
| Oncorhynchus sp. |
| Oncorhynchus sp. BZ-2002 |
| Oncorhynchus sp. FY-02 |
| Oncorhynchus sp. KD-2003 |
| Oncorhynchus tschawytscha |
| Oncorhynchus tshawytscha |
| Oncorhynchus tshawytscha (fish) |
| Oncorhynchus tshawytscha (homeopathic remedy) |
| Oncorhynchus tshawytscha (Walbaum, 1792) |
| Oncorhyncin III |
| Oncorhyncus kisutch |
| Oncornaviral Protein P19 |
| Oncornavirus |
| Oncornavirus, Type D |
| Oncornaviruses |
| Oncornaviruses, Type D |
| Oncosal |
| OncoScint |
| ONCOSCINT CR OV INJECTION 1 MG |
| OncoScint CR/OV |
| OncoScint CR103 |
| Oncosiphon |
| Oncosiphon grandiflorum |
| Oncosiphon suffruticosum |
| Oncosiphon suffruticosum (L.) Kallersjo |
| Oncosis |
| Oncosperma |
| Oncosperma horridum |
| Oncosperma tigillarium |
  67 68 69 70 71   |
